On August 17, 2021, PureTech Health plc (PureTech), a clinical-stage biotherapeutics company, announced that its Founded Entity, Akili Interactive (Akili), maker of EndeavorRx®, the first and only prescription video game treatment, and Australian digital health company TALi® (TALi), completed an agreement for Akili to license TALi’s technology designed to address early childhood attention impairments.

The terms of the deal, estimated at $37.5 million in future contingent milestone payments plus royalties on potential revenues, are structured to leverage each organization’s expertise. Building on their collective clinical development experience and Akili’s success in bringing EndeavorRx through the U.S. regulatory process and to market, the companies will work together to execute clinical trials of the TALi technology in pediatric ADHD and pursue U.S. Food and Drug Administration regulatory clearance. Under the terms of the agreement, Akili will lead U.S. commercialization and roll-out.

Through this agreement, Akili is expanding its leadership in prescription digital therapeutics for cognitive impairments and charting a path for a new patient demographic to benefit from innovative technologies proven to improve attention. TALi’s technology builds on Akili’s product portfolio and complements its flagship product EndeavorRx, which is FDA-cleared to improve attention function in children ages 8-12 with ADHD.

The Wilson Sonsini Goodrich & Rosati team that represented Akili in the transaction includes Allegra Sachs, Scott McKinney, James Huie, and Ian Edvalson.

For more information, please see the press release.